CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 35 enrolled
Drug / intervention
oral cannabinoid +1 moredrug
Likely dose
oral codeine/acetaminophen 30mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05477875
NCT05477875Phase 2Completed
CompareCT.gov

Randomized, Controlled Cross-over Comparison of Cannabinoid to Oral Opioid for Postoperative Photorefractive Keratectomy Pain Control

University of Florida·interventional·Posted Jul 28, 2022·Updated Aug 7, 2025

In Brief

A Phase 2 clinical trial evaluating oral cannabinoid and oral codeine/acetaminophen for Photorefractive Keratectomy and 2 related conditions. Completed, enrolled 35 participants across 1 site.

Detailed Summary

Photorefractive Keratectomy (PRK) is a commonly performed corneal refractive surgery but has significant post-operative pain. Pain medications after PRK are typically opioid-acetaminophen combinations. Alternatives to opioid medication are worth consideration. Patients will receive PRK in each eye sequentially, using the cannabinoid or codeine/acetaminophen for one eye and the other treatment for the fellow eye two weeks later.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPhotorefractive Keratectomy, Myopia, Hyperopia
CountriesUnited States
CollaboratorsConsortium for Medical Marijuana Clinical Outcomes Research

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedJul 28, 2022
Enrollment StartFeb 1, 2024
Primary CompletionJan 22, 2025
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 3.9 years ago

Interventions

oral cannabinoiddrug

dronabinol

oral codeine/acetaminophencombination

10 tablets of acetaminophen-codeine combination (300-30mg) without refills.